<DOC>
	<DOC>NCT00159822</DOC>
	<brief_summary>To evaluate the efficacy of voriconazole (VFend(R)) as first line treatment for proven chronic bronchopulmonary aspergillosis, in minimally immunocompromised or non-immunocompromised patients after 6 months of treatment i.e. chronic necrotizing pulmonary</brief_summary>
	<brief_title>Voriconazole For Chronic Bronchopulmonary Aspergillosis</brief_title>
	<detailed_description />
	<mesh_term>Aspergillosis</mesh_term>
	<mesh_term>Pulmonary Aspergillosis</mesh_term>
	<mesh_term>Voriconazole</mesh_term>
	<criteria>Patients with a chronic bronchopulmonary aspergillosis assessed by a compatible chest imagery (CT scan) and/or an endoscopic lesion sourced by photo, would it be: Complex aspergilloma non primarily operable, Chronic necrotizing pulmonary aspergillosis, Tracheobronchial aspergillosis, obstructive or necrotizing/pseudomembranous. Patient with risk factor(s) of cardiac arrhythmia, symptomatic arrhythmia, treated by medication known to prolong QT interval, or prolongation of QTc interval &gt; 450 msec in men and &gt; 470 msec in women. Simple aspergilloma with primary indication of surgical treatment.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
</DOC>